This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kruger, D. F. Articles by Sadler, C. E. Search for Related Content PubMed PubMed Citation Articles by Kruger, D. F. Articles by Sadler, C. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB GLUCOSE Social Bookmarking                         What's this?

New Insights Into Glucose Regulation

From Henry Ford Medical Center, Detroit, Michigan (Ms Kruger); Michigan Diabetes Research and Training Center, Ann Arbor, Michigan (Ms Martin); and Diabetes and Endocrine Associates, La Jolla, California (Mr Sadler).

Correspondence to Davida F. Kruger, Henry Ford Medical Center, New Center One, 3031 W. Grand Blvd, Suite 800, Detroit, MI 48202 (dkruger1{at}hfhs.org).

This review article describes the regulation of glucose homeostasis in subjects with and without diabetes based on the emergence of new information and discusses modes of action, attributes, and limitations of current diabetes therapies. In normal physiology, glucose homeostasis is tightly controlled by the interaction of pancreatic and gut hormones. Since the 1920s, diabetes has been viewed as a disease caused by deficient secretion of insulin, resulting in reduced glucose uptake and subsequent hyperglycemia. The discovery in the 1950s of the pancreatic hormone glucagon, which opposes insulin by increasing glucose appearance in the circulation, resulted in a bihormonal model of glucose homeostasis. More recently, with the discovery of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) in the 1970s and the pancreatic hormone amylin in the 1980s, it is now understood that several organs and hormones play roles in maintaining glucose homeostasis. Therapies for diabetes have focused on compensation for deficient insulin action through stimulation of insulin secretion, administration of insulin itself, reduction of peripheral insulin resistance, or decreased glucose absorption from the intestine. The discoveries of amylin and GLP-1 have furthered our understanding of the abnormalities involved in diabetes, enabling the development of additional therapeutic options.

The Diabetes Educator, Vol. 32, No. 2, 221-228 (2006)
DOI: 10.1177/0145721706286568


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. M. Funnell The Therapeutic Role of Incretin Mimetics and DPP-4 Inhibitors The Diabetes Educator, January 1, 2009; 35(Supplement_1): 12S - 17S. [Abstract] [Full Text] [PDF]